98%
921
2 minutes
20
Background: In 2016, the UN General Assembly set a global target of 3 million oral pre-exposure prophylaxis (PrEP) users by 2020. With this target at an end, we aimed to assess global trends in the adoption of WHO PrEP recommendations into national guidelines and numbers of PrEP users, defined as people who received oral PrEP at least once in a given year, and to estimate future trajectories of PrEP use.
Methods: In this global summary and forecasting study, data on adoption of WHO PrEP recommendations and numbers of PrEP users were obtained through the Global AIDS Monitoring system and WHO regional offices. Trends in these indicators for 2016-19 by region and for 2019 by country were described, including by gender and priority populations where data were available. PrEP user numbers were forecasted until 2023 by selecting countries with at least 3 years of PrEP user data as example countries in each region to represent possible future PrEP user trajectories. PrEP user growth rates observed in example countries were applied to countries in corresponding regions under different scenarios, including a COVID-19 disruption scenario with static global PrEP use in 2020.
Findings: By the end of 2019, 120 (67%) of 180 countries with data had adopted the WHO PrEP recommendations into national guidelines (23 in 2019 and 30 in 2018). In 2019, there were about 626 000 PrEP users across 77 countries, including 260 000 (41·6%) in the region of the Americas and 213 000 (34·0%) in the African region; this is a 69% increase from about 370 000 PrEP users across 66 countries in 2018. Without COVID-19 disruptions, 0·9-1·1 million global PrEP users were projected by the end of 2020 and 2·4-5·3 million are projected by the end of 2023. If COVID-19 disruptions resulted in no PrEP user growth in 2020, the projected number of PrEP users in 2023 is 2·1-3·0 million.
Interpretation: Widespread adoption of WHO PrEP recommendations coincided with a global increase in PrEP use. Although the 2020 global PrEP target will be missed, strong future growth in PrEP use is possible. New PrEP products could expand the PrEP user base, and, with greater expansion of oral PrEP, further adoption of WHO PrEP recommendations, and simplified delivery, PrEP could contribute to ending AIDS by 2030.
Funding: Unitaid, Bill & Melinda Gates Foundation, and WHO.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332196 | PMC |
http://dx.doi.org/10.1016/S2352-3018(21)00127-2 | DOI Listing |
BMJ Open
September 2025
Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Nairobi County, Kenya.
Introduction: Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective biomedical intervention for HIV prevention, but its access and utilisation are challenging, especially in high-burden settings such as Kenya. For potential PrEP users, long delays and repeated consultations with several providers are obstacles to both PrEP uptake and continuation. The One-Stop PrEP Care project aims to promote the use of PrEP among clients in the health system and enhance client satisfaction by reducing the waiting time.
View Article and Find Full Text PDFJ Acquir Immune Defic Syndr
September 2025
Minnesota Population Center, University of Minnesota Twin Cities, Minneapolis, MN, USA.
Introduction: Past research has shown that inflammation is reduced among marijuana-using HIV-negative people but not those living with HIV. We take this work a step further by assessing differences based on pre-exposure prophylaxis (PrEP) use among HIV-negative individuals.
Methods: NCHAT is a nationally-representative cohort study of 3,642 adult respondents who are married or cohabiting.
Sex Transm Infect
September 2025
Division of Clinical Epidemiology, University Hospital Basel and University of Basel, Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
Background: In 2018, Rwanda incorporated oral pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine (Truvada) into national HIV guidelines as part of a comprehensive HIV prevention programme for female sex workers (FSWs). This study assessed the impact of PrEP on HIV incidence among FSWs in urban Rwanda.
Methods: We conducted a retrospective cohort study among HIV-negative FSWs aged≥18 years at 20 health facilities in Kigali from January 2019 to October 2021.
Rev Bras Enferm
September 2025
Universidade de São Paulo. Ribeirão Preto, São Paulo, Brazil.
Objectives: to develop and validate an educational booklet on HIV Pre-Exposure Prophylaxis (PrEP).
Methods: quantitative validation study aimed at developing and validating an educational booklet by experts and the target audience. For validation with experts, we used the Health Education Content Validation Index developed in a virtual environment.
PLOS Glob Public Health
August 2025
Center for Biomedical Research, Population Council, New York, New York, United States of America.
Adolescent girls and young women (AGYW) in Zimbabwe bear a double burden of HIV and unmet need despite the progress made in provision of family planning and oral pre-exposure prophylaxis (PrEP). We elicited opinions from AGYW and health care providers (HCPs) about a dual prevention pill (DPP) in development that combines oral contraceptives (OCs) with oral PrEP to simultaneously prevent unintended pregnancy and HIV, and potentially increase uptake and adherence to oral PrEP. We enrolled 44 participants (March-June 2021) and conducted 12 in-depth interviews with HCPs (nurses, counselors, social workers, pharmacists, clinicians) from public and private health facilities offering HIV and family planning services in Harare, and four focus group discussions (FGDs) with 32 AGYW who were current OC users, stratified by age (16-19, 20-24).
View Article and Find Full Text PDF